A systematic approach for assessing next generation technologies and solutions in biomanufacturing

Amgen is one of the world's leading independent biotechnology companies and competes globally to advance important medicines in a highly competitive marketplace. Biologics manufacturers such as Amgen have traditionally invested in costly, large-scale stainless steel infrastructure to support the production of biologic medication. However, more recently, changes in the economics, such as the need to deploy less-capital intensive biomanufacturing plants faster, and advances in the technology, such as process-intensification (i.e., getting more protein from each cell), have created both incentives and pressures for smaller-scale, single-use, and modular production technologies. These incentives include greater flexibility, shorter timelines for construction / rapid deployment of new facilities, and reduced costs as well as physical and environmental footprint.

Name thesis:degree_name

Master

Department dc:contributor.department

Sloan School of Management

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2019

Author dc:creator

• Heslop, Janelle Nicole.

Advisor dc:contributor.advisor

• Heidi Nepf and Steve Spear.

• Sloan School of Management.
• Civil and Environmental Engineering.
• Leaders for Global Operations Program.

Statement dc:rights

• MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

https://hdl.handle.net/1721.1/122586

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/122586